SomnoMed Limited
SOMNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $111,493 | $91,651 | $83,616 | $72,580 |
| % Growth | 21.6% | 9.6% | 15.2% | – |
| Cost of Goods Sold | $44,763 | $36,520 | $37,847 | $33,428 |
| Gross Profit | $66,729 | $55,131 | $45,769 | $39,152 |
| % Margin | 59.9% | 60.2% | 54.7% | 53.9% |
| R&D Expenses | $1,818 | $1,300 | $881 | $1,087 |
| G&A Expenses | $20,191 | $18,013 | $14,150 | $13,813 |
| SG&A Expenses | $61,294 | $44,189 | $38,641 | $33,553 |
| Sales & Mktg Exp. | $22,914 | $26,176 | $24,491 | $19,740 |
| Other Operating Expenses | $0 | $17,972 | $10,320 | $8,643 |
| Operating Expenses | $63,112 | $63,461 | $49,842 | $43,284 |
| Operating Income | $3,617 | -$8,329 | -$4,073 | -$4,131 |
| % Margin | 3.2% | -9.1% | -4.9% | -5.7% |
| Other Income/Exp. Net | -$4,381 | -$2,941 | -$2,973 | $636 |
| Pre-Tax Income | -$764 | -$11,271 | -$7,045 | -$3,496 |
| Tax Expense | $2,692 | $971 | $822 | $931 |
| Net Income | -$3,456 | -$12,242 | -$7,999 | -$4,437 |
| % Margin | -3.1% | -13.4% | -9.6% | -6.1% |
| EPS | -0.016 | -0.1 | -0.097 | -0.054 |
| % Growth | 83.7% | -2.7% | -80.4% | – |
| EPS Diluted | -0.016 | -0.1 | -0.097 | -0.054 |
| Weighted Avg Shares Out | 211,915 | 120,718 | 82,149 | 82,143 |
| Weighted Avg Shares Out Dil | 211,910 | 120,717 | 82,149 | 82,143 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $30 | $2 | $0 |
| Interest Expense | $381 | $3,167 | $2,627 | $380 |
| Depreciation & Amortization | $1,894 | $5,775 | $1,623 | $1,429 |
| EBITDA | $1,583 | -$2,329 | -$3,117 | -$1,983 |
| % Margin | 1.4% | -2.5% | -3.7% | -2.7% |